Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07806604) titled 'Real World Study of Icotinib in Adjuvant Post Surgical Treatment for Stage IA2 High Risk to IB EGFR Mutant Non Small Cell Lung Cancer' on Sept. 2.

Study Type: Observational

Primary Sponsor: Betta Pharmaceuticals Co., Ltd.

Condition: NSCLC (Non-small Cell Lung Cancer)

Intervention: Drug: Icotinib

Recruitment Status: Recruiting

Date of First Enrollment: September 2026

Target Sample Size: 2572

Countries of Recruitment: China

To know more, visit https://clinicaltrials.gov/study/NCT07806604

Disclaimer: Curated by HT Syndication....